Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca has revealed results from a randomised, double-blind, multicenter, placebo-controlled Phase II clinical trial evaluating olaparib in patients who are suffering from platinum-sensitive relapsed serous ovarian cancer (SOC), following the completion of chemotherapy.
Subscribe to our email newsletter
The results of the trial suggested that olaparib 400mg twice daily extended progression free survival (PFS) by RECIST compared to placebo Median PFS: 8.4 vs 4.8 months respectively.
Olaparib also prolonged the secondary endpoint of time to progression (TTP) by CA-125 or RECIST Median TTP 8.3 vs 3.7 months respectively.
AstraZeneca Medical Science director Jane Robertson said these results are encouraging as they suggest that olaparib may have a positive effect on PFS in women with serous ovarian cancer, and may be a valuable therapeutic option for this aggressive form of cancer.